Viz.ai said yesterday that it received $50 million in Series B funding for its artificial intelligence software for treating acute ischemic stroke.
The San Francisco-based company uses a computer-aided triage system designed to identify a suspected large vessel occlusion via CT scan and alerts a stroke team specialist within minutes, reducing the time to treatment and increasing chances of a positive outcome.
The company said its software is available in 300 hospitals across the U.S. In July, Medtronic inked a deal to distribute Viz.ai’s stroke-detection software, saying it aimed to place it in every U.S. stroke center.
In July 2018, Viz.ai raised $21 million in a Series A funding round joined by GV, formerly known as Google Ventures, to support market expansion and to extend its product portfolio beyond stroke care.
The company’s latest funding round was led by Greenoaks and included participation from Threshold Ventures, CRV, along with existing investors GV and Kleiner Perkins.
“Viz.ai’s mission is to improve access to lifesaving treatments,” CEO Chris Mansi said in prepared remarks. “In stroke, by saving time for the hospital system, we can achieve significant cost savings for the payer and most importantly, improved outcomes for the patient. This round of funding will enable us to expand the benefits of synchronized care to more disease states and geographies, democratizing the quality of health care globally.”
“Viz.ai shortens time to treatment, increases the number of patients able to receive lifesaving therapy, and allows us to provide the best care for our patients,” added Dr. J Mocco of New York City’s Mount Sinai Health System. “With stroke being the number one cause of long-term disability, every minute counts. Viz.ai is reducing the impact of this devastating disease and saving lives.”